PDCD1 and neoplasm: Therefore, the levels of PD-L1 around the tumor microenvironment cannot be considered an optimal biomarker for patient selection and lack of PD-L1 expression cannot be reliably used to exclude patients from treatment with PD1 pathway blockade.